These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A two year observation of the process of applying recombinant IGF-1 to treat short stature in children with primary IGF-1 deficiency -- case reports of 3 patients. Petriczko E; Wikiera B; Horodnicka-Józwa A; Marcinkiewicz K; Szmit-Domagalska J; Kędzia A; Durzyńska J; Broniarczyk J; Gabryelczyk B; Noczyńska A; Walczak M Pediatr Endocrinol Diabetes Metab; 2011; 17(4):233-8. PubMed ID: 22248785 [TBL] [Abstract][Full Text] [Related]
3. Mecasermin Tercica. Norman P Curr Opin Investig Drugs; 2006 Apr; 7(4):371-80. PubMed ID: 16625824 [TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options. Kemp SF BioDrugs; 2009; 23(3):155-63. PubMed ID: 19627167 [TBL] [Abstract][Full Text] [Related]
5. Managing the child with severe primary insulin-like growth factor-1 deficiency (IGFD): IGFD diagnosis and management. Cohen J; Blethen S; Kuntze J; Smith SL; Lomax KG; Mathew PM Drugs R D; 2014 Mar; 14(1):25-9. PubMed ID: 24639006 [TBL] [Abstract][Full Text] [Related]
10. Treatment of severe primary IGF-1 deficiency using rhIGF-1 preparation - first three years of Polish experience. Petriczko E; Jackowski T; Horodnicka-Józwa A; Wikiera B; Noczyńska A; Korpal-Szczyrska M; Birkholz-Walerzak D; Małecka-Tendera E; Kalina-Fraska B; Kalina M; Barg E; Beń-Skowronek I; Szewczyk L; Hilczer M; Smyczyńska J; Stawerska R; Lewiński A; Ziora K; Bossowski A; Pietrewicz E; Pyrżak B; Kędzia A; Szalecki M; Kilian A; Walczak M Endokrynol Pol; 2019; 70(1):20-27. PubMed ID: 30351442 [TBL] [Abstract][Full Text] [Related]
11. Desensitization to mecasermin in an insulin-like growth factor 1-deficient patient. Gutiérrez-Fernández D; Moreno-Ancillo Á; Foncubierta-Fernández A; López-Martínez I; Lechuga-Sancho A; Fernández-Anguita MJ Ann Allergy Asthma Immunol; 2015 Jun; 114(6):523-5. PubMed ID: 25843163 [No Abstract] [Full Text] [Related]
12. Insulin-like growth factor I and insulin and their abuse in sport. Erotokritou-Mulligan I; Holt RI Endocrinol Metab Clin North Am; 2010 Mar; 39(1):33-43, viii. PubMed ID: 20122448 [TBL] [Abstract][Full Text] [Related]
15. Recombinant human insulin-like growth factor-I therapy for children with growth disorders. Richmond EJ; Rogol AD Adv Ther; 2008 Dec; 25(12):1276-87. PubMed ID: 19066756 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of rhIGF-1 Therapy in Children: The European Increlex® Growth Forum Database Experience. Bang P; Polak M; Woelfle J; Houchard A; Horm Res Paediatr; 2015; 83(5):345-57. PubMed ID: 25824333 [TBL] [Abstract][Full Text] [Related]
17. Adult and near-adult height in patients with severe insulin-like growth factor-I deficiency after long-term therapy with recombinant human insulin-like growth factor-I. Backeljauw PF; Kuntze J; Frane J; Calikoglu AS; Chernausek SD Horm Res Paediatr; 2013; 80(1):47-56. PubMed ID: 23887143 [TBL] [Abstract][Full Text] [Related]
18. Off-label use of recombinant igf-I to promote growth: is it appropriate? Rosenbloom AL; Rivkees SA J Clin Endocrinol Metab; 2010 Feb; 95(2):505-8. PubMed ID: 20133470 [No Abstract] [Full Text] [Related]